Aspen’s South African subsidiary, Pharmacare, has entered into a preliminary agreement with Johnson & Johnson to manufacture its investigational COVID-19 vaccine candidate, Ad26.COV2-S.
The vaccine candidate is currently undergoing clinical trials. Aspen Pharmacare will perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson.
The agreement is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.
Aspen Pharmacare has agreed to provide the necessary capacity required for the manufacture of Johnson & Johnson’s COVID-19 vaccine candidate at its existing sterile facility in Port Elizabeth, South Africa.
Stephen Saad, Aspen Group Chief Executive said “We have invested globally in our sterile capability and are determined to play a role in the manufacture of vaccines to add to our proud track record of making contributions to humanity in times of global pandemics.
“This has included, inter alia, being a leading global supplier for antiretrovirals for the treatment of HIV/AIDS, multi-drug-resistant-TB products and COVID-19-related treatments such as anaesthetics and dexamethasone.
“We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus. We are particularly pleased to be given the opportunity of providing assistance for patients in need across the world from our South African base.”